SCHEMBL1419741

SCHEMBL1419741

CC(=O)Cc1cnc(Br)s1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.40
ALDH1A1 P00352 3/20 0.35
NPC1 O15118 1/20 0.35
MITF O75030 1/20 0.35
S1PR4 O95977 1/20 0.35
MAPT P10636 1/20 0.35
S1PR1 P21453 1/20 0.35
RAB9A P51151 1/20 0.35
TSHR P16473 2/20 0.35
PDK1 Q15118 1/20 0.34
PDK2 Q15119 1/20 0.34
PDK3 Q15120 1/20 0.34
PDK4 Q16654 1/20 0.34
FPR2 P25090 1/20 0.33
CCNE1 P24864 2/20 0.33
CDK2 P24941 2/20 0.33
CDK5 Q00535 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.32
MAPK10 P53779 1/20 0.32
HDAC1 Q13547 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27719736 0.82 SMN1; SMN2 (0.38) SMN1; SMN2ALDH1A1MAPTTSHRFPR2
SCHEMBL25564576 0.80 HCAR2 (0.47) SMN1; SMN2ALDH1A1NPC1MAPTRAB9A
SCHEMBL15522867 0.79 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1NPC1RAB9ATSHR
SCHEMBL18116435 0.78 SMN1; SMN2 (0.63) SMN1; SMN2ALDH1A1MAPTTSHRL3MBTL1
SCHEMBL7453226 0.77 SMN1; SMN2 (0.69) SMN1; SMN2ALDH1A1NPC1MAPTTSHR
Bicarbonate SCHEMBL27848216 0.76 CCNE1 (0.45) SMN1; SMN2PDK1PDK2PDK3PDK4
SCHEMBL1419367 0.74 SMN1; SMN2 (0.36) SMN1; SMN2TSHRCCNE1CDK2CDK5
SCHEMBL4972075 0.74 LMNA (0.53) ALDH1A1MAPTTSHRCCNE1CDK2
SCHEMBL606580 0.72
SCHEMBL3072164 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270879-A1 Heterocyclic Compounds As CCR1 Receptor Antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-25 US disclosed
EP-2493875-A1 HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-09-05 EP disclosed
EP-2346868-A1 AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-27 EP disclosed
WO-2011056440-A1 HETEROCYCLIC COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-12 WO disclosed
EP-2297112-A1 PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2011-03-23 EP disclosed
WO-2010036632-A1 AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-01 WO disclosed
WO-2009137338-A1 PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-11-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270879-A1 Heterocyclic Compounds As CCR1 Receptor Antagonists CCR1, CCRL2, CCR3 SMN1; SMN2 2616/4885ALDH1A1 552/4885NPC1 845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.